Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation

Onat, A.; Can, G.; Hergenc, G.; Yazici, M.; Karabulut, AHMET; Albayrak, S.

doi:10.1038/sj.ijo.0803552

Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation

Copy For Citation

Onat A., Can G., Hergenc G., Yazici M., Karabulut A. , Albayrak S.

INTERNATIONAL JOURNAL OF OBESITY, vol.31, no.7, pp.1119-1125, 2007 (Journal Indexed in SCI)

Publication Type: Article / Article
Volume: 31 Issue: 7
Publication Date: 2007
Doi Number: 10.1038/sj.ijo.0803552
Title of Journal : INTERNATIONAL JOURNAL OF OBESITY
Page Numbers: pp.1119-1125

Abstract

Objectives: To investigate the role of serum apolipoprotein (apo) B levels in predicting metabolic syndrome (MS), hypertension, atherogenic dyslipidemia and type II diabetes.